Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Compugen Ltd. (CGEN.TA)
Holon, IL
Compugen Ltd. is a clinical-stage biotechnology company engaged in the discovery, development, and commercialization of innovative therapeutic candidates across Israel, the United States, and Europe. The company's primary focus is immuno-oncology, with a robust pipeline of investigational treatments. Key assets in their immuno-oncology portfolio include: COM701, an anti-PVRIG antibody, currently in Phase I clinical trials for the treatment of solid tumors. COM902, a therapeutic antibody targeting TIGIT, also in Phase I, being evaluated as a monotherapy in patients with advanced malignancies. Bapotulimab, an antibody designed to target ILDR2, which is undergoing Phase I clinical study for solid tumors. AZD2936, a novel bispecific antibody that targets both TIGIT and PD-1, advancing through Phase I/II clinical studies in patients with advanced or metastatic non-small cell lung cancer. Beyond these clinical-stage programs, Compugen is also pursuing early-stage immuno-oncology research, with a particular emphasis on myeloid targets. The company maintains significant strategic alliances, including: A collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against Compugen's proprietary immune checkpoint regulators. A partnership with Bristol-Myers Squibb to assess the safety and tolerability of COM701 when combined with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo, in advanced solid tumor patients. An engagement with Johns Hopkins School of Medicine to explore novel T cell and myeloid checkpoint targets. A licensing agreement with AstraZeneca for the development of bispecific and multispecific immuno-oncology antibody products. A research collaboration with Johns Hopkins University focusing on myeloid research. Compugen Ltd. was founded in 1993 and is headquartered in Holon, Israel.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.40% | +4.30% | -3.16% | +58.79% | +61.57% | +77.69% | +68.89% | +199.68% | -67.90% | -68.24% | +10.88% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+161.1% ★ Q1'26: -4.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+337.5% ★ Q1'26: -6.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+35.9% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+43.1% ★ Q1'26: -414.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +98.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+4.8% Q1'26: +2.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.09× ★ Q1'26: -0.08× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2021 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 1 EPS Ana. |
Dec 2027 5 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
9.28M
est: 5.40M (+71.9%)
|
712.0K
est: 749.3K (-5.0%)
|
—
est: 442.8K (-100.0%)
|
17.80M
est: 19.12M (-6.9%)
|
6.00M
est: 6.75M (-11.1%)
|
33.46M
est: 22.80M (+46.8%)
|
27.86M
est: 37.60M (-25.9%)
|
72.76M
est: 7.04M (+934.3%)
|
10.24M
10.24M – 10.24M
+45.5% YoY
|
24.68M
24.68M – 24.68M
+141.1% YoY
|
33.76M
33.76M – 33.76M
+36.8% YoY
|
31.19M
31.19M – 31.19M
-7.6% YoY
|
37.09M
37.09M – 37.09M
+18.9% YoY
|
| EBITDA |
-19.81M
est: -4.20M (-371.6%)
|
-31.10M
est: -583.1K (-5,233.6%)
|
-37.41M
est: -344.6K (-10,754.3%)
|
-21.83M
est: -14.88M (-46.7%)
|
-34.61M
est: -5.25M (-559.2%)
|
-12.52M
est: -17.74M (+29.4%)
|
-14.41M
est: -18.45M (+21.9%)
|
31.80M
est: -3.45M (+1,021.0%)
|
-5.02M
-5.02M – -5.02M
-45.5% YoY
|
-12.11M
-12.11M – -12.11M
-141.1% YoY
|
-16.57M
-16.57M – -16.57M
-36.8% YoY
|
-15.31M
-15.31M – -15.31M
+7.6% YoY
|
-18.20M
-18.20M – -18.20M
-18.9% YoY
|
| EBIT |
-20.92M
est: -4.24M (-393.9%)
|
-32.58M
est: -587.8K (-5,442.9%)
|
-37.41M
est: -347.4K (-10,666.7%)
|
-23.23M
est: -15.00M (-54.8%)
|
-35.07M
est: -5.29M (-562.5%)
|
-12.99M
est: -17.88M (+27.4%)
|
-14.89M
est: -18.74M (+20.5%)
|
31.33M
est: -3.51M (+993.4%)
|
-5.10M
-5.10M – -5.10M
-45.5% YoY
|
-12.30M
-12.30M – -12.30M
-141.1% YoY
|
-16.83M
-16.83M – -16.83M
-36.8% YoY
|
-15.55M
-15.55M – -15.55M
+7.6% YoY
|
-18.49M
-18.49M – -18.49M
-18.9% YoY
|
| Net Income |
-20.16M
est: -45.24M (+55.4%)
|
-31.51M
est: -55.75M (+43.5%)
|
-37.07M
est: -65.20M (+43.1%)
|
-22.60M
est: -41.84M (+46.0%)
|
-34.20M
est: -39.21M (+12.8%)
|
-18.75M
est: -17.41M (-7.7%)
|
-14.23M
est: -6.57M (-116.7%)
|
35.34M
est: -28.14M (+225.6%)
|
-21.24M
-21.24M – -21.24M
+24.5% YoY
|
-20.37M
-20.37M – -20.37M
+4.1% YoY
|
-21.03M
-21.03M – -21.03M
-3.2% YoY
|
-33.95M
-33.95M – -33.95M
-61.5% YoY
|
-30.00M
-30.00M – -30.00M
+11.6% YoY
|
| SGA |
7.32M
est: 10.20M (-28.2%)
|
8.52M
est: 1.42M (+502.1%)
|
8.82M
est: 836.6K (+954.6%)
|
9.68M
est: 36.13M (-73.2%)
|
11.70M
est: 12.75M (-8.2%)
|
9.98M
est: 43.06M (-76.8%)
|
10.02M
est: 31.86M (-68.6%)
|
9.43M
est: 5.96M (+58.2%)
|
8.67M
8.67M – 8.67M
+45.5% YoY
|
20.92M
20.92M – 20.92M
+141.1% YoY
|
28.61M
28.61M – 28.61M
+36.8% YoY
|
26.44M
26.44M – 26.44M
-7.6% YoY
|
31.43M
31.43M – 31.43M
+18.9% YoY
|
| EPS |
-0.40
est: -0.51 (+20.8%)
|
-0.62
est: -0.62 (+0.4%)
|
-0.72
est: -0.73 (+1.1%)
|
-0.41
est: -0.47 (+12.3%)
|
-0.41
est: -0.44 (+6.4%)
|
-0.21
est: -0.19 (-8.0%)
|
-0.16
est: -0.07 (-128.6%)
|
0.38
est: -0.30 (+226.7%)
|
-0.23
-0.23 – -0.23
+24.5% YoY
|
-0.22
-0.22 – -0.22
+4.1% YoY
|
-0.22
-0.22 – -0.22
-3.2% YoY
|
-0.36
-0.36 – -0.36
-61.5% YoY
|
-0.32
-0.32 – -0.32
+11.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-05 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-04 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-01 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Responsible International Equity ETF AVSD | 0.01% | 36.5K | 0.23% |
| 2 | Avantis Global Small Cap Value UCITS ETF AVGS.L | 0.01% | 67.8K | 0.39% |
| 3 | Avantis International Small Cap Value ETF AVDV | 0.00% | 336.0K | 0.36% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Anat Cohen-Dayag | Executive Chair | 743.1K | — |
| Michelle Mahler | Chief Medical Officer | 581.8K | female |
| Pierre Ferre | Chief Operating Officer | 471.4K | — |
| Eran Ophir | Chief Executive Officer, President & Director | 312.2K | — |
| Zurit Levine | Senior Vice President of Business Development | 303.7K | — |
| David Silberman | Chief Financial Officer | — | male |
| Eran Ben Dor | General Counsel & Corporate Secretary | — | male |
| Rivka Schwartz | Vice President Research and Discovery | — | — |
| Sharon Kredo-Russo | Senior Vice President of Research & Discovery | — | — |
| Dorit Amitay | Vice President of Human Resources | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CGEN.TA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
